What is IMVT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.29B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMVT?

P/E (TTM) is n/a and 52-week range is $16.08 to $45.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMVT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMVT?

The company profile lists net income (TTM) near $-580M, EPS (TTM) near $-2.81 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Immunovant Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 206.4M shares outstanding, ISIN US45258J1025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Immunovant Inc

$IMVT

Health Care · Biotechnology

IR Run Scenarios

$30.47

+0.69%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Employees

362

Website

immunovant.com/

IPO

2019-05-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)